China Quality Yk11 Sarms Powder Domestic Yk 11 Factory Price, Find details about China Sarm Yk 11, Yk 11 Sarm from Quality Yk11 Sarms Powder Domestic Yk 11 Factory Price
In general, SARMs offer three key benefits - increased muscle mass, decreased fat mass, and increased bone mass.
SARM aren't just designed and meant for athletes; as previously discussed there are a slew of populations that could benefit from SARMs.
Those with one or more of the following conditions could benefit from SARMs: muscle wasting disorders (such as : sarcopenia, amyotrophic lateral sclerosis, and cystic fibrosis), sports injuries, burn injuries, weakness and/or body wasting due to cancer or HIV, and frailty and/or muscle atrophy as a result of the aging process.
Although there are many drugs designed to improve the health of these populations, SARMs also have the unique benefit of being non-methylated and non-aromatized by the body, so they're not toxic to the liver nor do they convert in to other active androgen or estrogen compounds. Liver toxicity and aromatization is a very serious concern when using pro-hormones and AASs. As you can see, SARMs benefit both chronically ill individuals as well healthy individuals looking to maximize quality of life.
Furthermore, SARM have demonstrated the ability to minimize or prevent muscle trophy when muscles were immobilized in casts. This is great news for athletes who work hard on the field and in the weight room to build muscle mass, strength, and power as SARM may positively impact the recovery process.
Name | CAS NO. | Usage |
AICAR | 2627-69-2 | acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
MK2866 | 841205-47-8 | medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
MK-677 | 15972-10-0 | for the treatment of frailty in the elderly |
LGD-4033 | 1165910-22-4 | pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
GW1516 | 317318-70-0 | For obesity, diabetes, dyslipidemia and cardiovascular disease |
Andarine(S4) | 401900-40-0 | partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
SR9009 | 1379686-30-2 | under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
RAD140 | 1182367-47-0 | New generation for gaining mass and cutting edges |
YK11 | 431579-34-9 | YK11: a SARM and myostatin inhibitor in one |
AC262356 | 870888-46-3 | New SARMS |
SR9011 | 1379686-29-9 | New SARMS |
S23 | 1010396-29-8 | New SARMS |
GW0724 | 317318-84-6 | New SARMS |